← Back to Search

Dietary Supplement

QuadraMune(TM) for Prevention of COVID-19

N/A
Waitlist Available
Led By James Veltmeyer, MD
Research Sponsored by Therapeutic Solutions International
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if QuadraMune(TM), a natural supplement, can help prevent COVID-19 in high-risk individuals by reducing inflammation and boosting the immune system over a few months.

Eligible Conditions
  • Coronavirus
  • Coronavirus Infection
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Prevention of COVID-19
Secondary study objectives
Safety as determined by presence or absence of Adverse Events and Serious Adverse Events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
Patients will receive 2 pills of QuadraMune(TM) daily for 12 weeks

Find a Location

Who is running the clinical trial?

Therapeutic Solutions InternationalLead Sponsor
2 Previous Clinical Trials
60 Total Patients Enrolled
James Veltmeyer, MDPrincipal InvestigatorTherapeutic Solutions International
1 Previous Clinical Trials
30 Total Patients Enrolled
~91 spots leftby Dec 2025